Conference abstract · 11 Jan 2023
Case reportPublished 24 Mar 2021
Neuroleptic Malignant Syndrome Associated with Venlafaxine: A Rare Side Effect
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Neuroleptic Malignant Syndrome (NMS) is an infrequent but a potentially life-threatening emergency, associated with the use of neuroleptic and antipsychotic medications. It is characterised by tetrad of symptoms including fever, rigidity, altered mental status and autonomic dysfunction. Few cases of NMS have been reported to be caused by use of Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI). NMS was first described in 1960 with the use of Haloperidol. It has been associated with virtually all neuroleptics including newer atypical antipsychotics. The incidence rate ranges from 0.02% to 3%. However, the incidence rate as decreased with newer neuroleptics to 0.01% to 0.02%. Due to its life-threatening nature, NMS requires prompt diagnosis and treatment, ruling out similar conditions such as Serotonin Syndrome and Malignant Hyperthermia. A 60-year-old female was admitted with one week of paranoia, hallucination, incomprehensible speech and a background history of Parkinson disease, anxiety and depression. She was on Sinemet plus 25/100 five times a day. Amantadine 100 mg once a day, Clonazepam 500 mg at night, Venlafaxine 150 mg twice a day. Her Amantadine and Sinemet plus was stopped 1/52 prior to admission in community and Venlafaxine was stopped on admission. Few days later she developed persistent hyperthermia, raised CK and Lactate. A diagnosis of NMS was made, and improvement was seen with Dantrolene along with supportive measures. Patient was stabilised for discharge and her Venlafaxine was reintroduced. She had a relapse of her symptoms with high grade fever, confusion and rigidity. This case emphasizes the need and importance of re-introducing non-neuroleptic medications at an early stage of recovery which resulted in relapse of NMS, a rare side effect of venlafaxine.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in General Medicine: Open Access.
Conference abstract · 11 Jan 2023
Massive pericardial effusion in a 9-year-old female with covid-19 associated multisystem inflammatory syndrome in children (mis-c): A case report
Conference abstract · 11 Jan 2023
Study of the prognostic factors of the relapse of laryngeal cancer after postoperative radiotherapy at the Cancer Center Emir Abdelkader of Oran Algeria
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalGeneral Medicine: Open Access
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Fareena Yasir”